Lupin receives USFDA approval for travoprost ophthalmic solution
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
ORACEA is a trademark of Galderma Holdings, S.A.
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Subscribe To Our Newsletter & Stay Updated